Startup profile · funding coverage
Tandem Health funding, valuation and investors
European AI medical assistant — scribe, coding, and clinical decision support certified as Class IIa MDR devices.
Keep track of Tandem Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$100M · September 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$150M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Sweden (pan-European)
Investors in latest funding
Lead: Scaleup Europe Fund (EQT)
Other: Kinnevik , Northzone , Amino Collective , Visionaries
Overview
Tandem Health builds an AI Medical Assistant for European clinicians: pre-chart summaries, in-visit decision support, and automated documentation, coding, and task management after the visit. The company says its AI Scribe, Coding Assistant, and Clinical Decision Support are each independently certified as Class IIa medical devices under the EU MDR, with integrations into more than 130 medical-record systems. Founded by CEO Lukas Saari and based in Sweden with offices across Europe, Tandem raised a $50M Series A in 2025 and a $100M Series B led by the EQT-managed Scaleup Europe Fund in September 2026, bringing total funding to $160M.
Why Tandem Health is interesting
Scaleup Europe Fund’s first healthcare check: $100M Series B (Sep 2026) behind a pan-European clinic AI already in 10,000 care organisations across 14 markets, with Accurx distributing into NHS workflows.
Product & use cases
AI Medical Assistant spanning pre-visit prep, in-visit clinical decision support, and post-visit documentation, coding, and tasks — expanding toward an AI-native clinic operating system for triage, scheduling, and patient communications.
- Ambient clinical documentation and coding for European care providers
- MDR-certified clinical decision support inside the visit
- Clinic workflow orchestration across 130+ regional EHR systems
Key facts
- $100M Series B led by Scaleup Europe Fund (EQT) — first healthcare investment for the fund (Sep 14, 2026)
- Company: 10,000 care organisations across 14 European markets; 130+ EHR integrations
- Named customers / partners: Ramsay Santé, Humanitas, NHS via Accurx (company / Sky News)
- Peer-reviewed claim: 29% less admin time, 30% higher job satisfaction, 30% less admin stress
Funding history (newest first)
Series B
2026-09 $100M- Scaleup Europe Fund (EQT) (lead)
- Kinnevik (participant)
- Northzone (participant)
- Amino Collective (participant)
- Visionaries (participant)
Series A
2025 $50M- Kinnevik
- Northzone
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Tandem Health's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.